The Limited Times

Now you can see non-English news...

Ten years after the Mediator affair, Servier continues to moult

2020-02-20T16:41:50.844Z


If some feared for its survival, the laboratory has managed to weather the legal and media storm. The company, which has revived its R&D, now has thirty drugs in development.


Ten years after the Mediator case began, Servier has changed its face. If its image remains marked by the 1,500 deaths caused by this drug, the French laboratory has been profoundly transformed. However, it will still take time to turn the page. While the trial opened on September 23 before the Paris Criminal Court, the indictment of the prosecution is scheduled for late April. The judgment could then be put under advisement. "Patients have the right to the truth," insists the director general of the laboratory, Olivier Laureau.

Read also: Our file on the Mediator case: all you need to know about this extraordinary trial

If some feared for his survival, Servier managed to weather the legal and media storm. It recorded last year (financial year ended September 30, 2019) a turnover of 4.6 billion euros, an increase of 10.5%, divided between its core drug activity (70% of sales) and generics (30%). Its operating profit was however weighed down (-34%) by a series of acquisitions and investments. The

This article is for subscribers only. You still have 73% to discover.

Subscribe: € 1 for 2 months

cancellable at any time

Enter your email

Already subscribed? Login

Source: lefigaro

All business articles on 2020-02-20

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.